Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr 1;211 Suppl 2(Suppl 2):S50-7.
doi: 10.1093/infdis/jiu816.

Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosis

Affiliations
Review

Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosis

Hugh Salamon et al. J Infect Dis. .

Abstract

Tuberculosis remains a major global public health challenge. Although incidence is decreasing, the proportion of drug-resistant cases is increasing. Technical and operational complexities prevent Mycobacterium tuberculosis drug susceptibility phenotyping in the vast majority of new and retreatment cases. The advent of molecular technologies provides an opportunity to obtain results rapidly as compared to phenotypic culture. However, correlations between genetic mutations and resistance to multiple drugs have not been systematically evaluated. Molecular testing of M. tuberculosis sampled from a typical patient continues to provide a partial picture of drug resistance. A database of phenotypic and genotypic testing results, especially where prospectively collected, could document statistically significant associations and may reveal new, predictive molecular patterns. We examine the feasibility of integrating existing molecular and phenotypic drug susceptibility data to identify associations observed across multiple studies and demonstrate potential for well-integrated M. tuberculosis mutation data to reveal actionable findings.

Keywords: database; drug resistance; drug susceptibility testing; genomic sequencing; resistance-associated mutations; tuberculosis.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Jain A, Mondal R. Extensively drug-resistant tuberculosis: current challenges and threats. FEMS Immunol Med Microbiol. 2008;53:145–50. - PubMed
    1. Van Deun A, Wright A, Zignol M, Weyer K, Rieder HL. Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. Int J Tuberc Lung Dis. 2011;15:116–24. - PubMed
    1. Angra PK, Taylor TH, Iademarco MF, Metchock B, Astles JR, Ridderhof JC. Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008. J Clin Microbiol. 2012;50:1233–9. - PMC - PubMed
    1. Jiang G-L, Chen X, Song Y, Zhao Y, Huang H, Kam KM. First proficiency testing of second-line anti-tuberculosis drug susceptibility testing in 12 provinces of China. Int J Tuberc Lung Dis. 2013;17:1491–4. - PubMed
    1. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005–15. - PMC - PubMed

Publication types

Substances